Dr. Oliver Steffen Fetzer, Ph.D., MBA, has been the Chief Executive Officer at Synthetic Genomics, Inc. since October 27, 2014. Dr. Fetzer has extensive experience in successful clinical development, deal transactions and biopharmaceuticals leadership over his more than 20 years in the industry. He served as the Chief Executive Officer and President of Cerulean Pharma Inc. from April 8, 2009 to October 29, 2014. Dr. Fetzer served as a Senior Vice President of Corporate Development and Research & Development at TerraGen Discovery, Inc. from July 2004 to September 2007. From January 2003 to July 2004, Dr. Fetzer served as a Senior Vice President of Corporate Development and Chief Business Officer at Cubist Pharmaceuticals Inc. From July 2002 to January 2003, he served as a Senior Vice President of Business Development at Cubist Pharmaceuticals Inc. He served as Consultant at the Boston Consulting Group from 1993 to 1995, Vice President from 2000 to 2002, Manager from 1997 to 2000, Project Leader until 1997, Managing Director, Principal and Partner. Dr. Fetzer focused on domestic and international strategic issues, predominantly in the healthcare industry, covering all functions of the pharmaceutical value chain. He has been an Independent Director of Arena Pharmaceuticals, Inc. since February 14, 2017. He has been a Director of Tecan Group Ltd. (alternate name, Tecan Group AG) since April 2011 and Synthetic Genomics, Inc. since October 27, 2014. He served as a Director of Auxilium Pharmaceuticals Inc. from December 6, 2005 to January 29, 2015. He served as a Director of Cerulean Pharma Inc., from April 8, 2009 to October 29, 2014. He served as a Director of Boston Consulting Group from 2000 to 2002. He holds a B.S. in Biochemistry from the College of Charleston (South Carolina), a Ph.D in Pharmaceutical Sciences from the Medical University of South Carolina and an MBA from Carnegie Mellon University.

Biochemistry, Synthetic Genomics